HomeComparePFE vs BSX

PFE vs BSX: Dividend Comparison 2026

PFE yields 6.20% · BSX yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $30.9K in total portfolio value· pulled ahead in Year 8
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →

Portfolio growth — PFE vs BSX

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFEBSX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + BSX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
BSX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
At 15% tax rate, PFE beats the other by $23,128.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + BSX for your $10,000?

PFE: 50%BSX: 50%
100% BSX50/50100% PFE
Portfolio after 10yr
$35.7K
Annual income
$13,605.43/yr
Blended yield
38.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
BSX buys
6
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Kevin Hern🏢 House$BSX▼ Sell$15,001 - $50,0002025-10-28
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-10-17
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFEBSX
Forward yield6.20%3.18%
Annual dividend / share$1.72$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%-50%
Portfolio after 10y$51.1K$20.2K
Annual income after 10y$27,210.54$0.32
Total dividends collected$60.1K$321.00
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusHoldBuy
Analyst price target$27.50$108.35

Year-by-year: PFE vs BSX ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrBSX PortfolioBSX Income/yrGap
1$9,161$701.38$10,859$158.91$1.7KBSX
2$8,610$859.79$11,700$80.63$3.1KBSX
3$8,366$1,081.25$12,559$40.60$4.2KBSX
4$8,483$1,405.66$13,459$20.36$5.0KBSX
5$9,084$1,907.24$14,411$10.20$5.3KBSX
6$10,418$2,732.78$15,425$5.10$5.0KBSX
7$13,007$4,193.56$16,507$2.55$3.5KBSX
8← crossover$18,010$7,005.87$17,664$1.28+$346.00PFE
9$28,216$12,979.89$18,901$0.64+$9.3KPFE
10$51,081$27,210.54$20,225$0.32+$30.9KPFE

PFE vs BSX: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →
📬

Get this PFE vs BSX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.